X4 Pharmaceuticals is like a smaller, late-stage clinical version of Alexion Pharmaceuticals, but focused on rare immunodeficiencies and blood disorders.

Consider X4 Pharmaceuticals a burgeoning Vertex Pharmaceuticals, specializing in rare immune system and blood disorders rather than genetic lung diseases.

• mavorixafor: A small molecule inhibitor of CXCR4 in late-stage clinical trials for WHIM syndrome, chronic neutropenia, and Waldenström macroglobulinemia.
• X4P-002: A CXCR4 antagonist under development for the treatment of brain cancers.
• X4P-003: A CXCR4 antagonist in development for CXCR4 disorders and primary immunodeficiencies.

Major Customers

As a late-stage clinical biopharmaceutical company, X4 Pharmaceuticals (XFOR) is primarily engaged in research and development, with its lead product candidates still in clinical trials. Consequently, it does not currently have major commercial sales to individual patients or a broad network of traditional distributors and pharmacies.

However, the company does have a significant business-to-business relationship that can be considered a customer-like arrangement:

• Abbisko Therapeutics Co., Ltd. (HKEX: 2256) is a licensee of X4 Pharmaceuticals. Under a license agreement, Abbisko Therapeutics has the rights to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications in certain regions.

Adam Craig, Ph.D. Executive Chairman of the Board, Principal Executive Officer

Dr. Craig was appointed Executive Chairman of the Board and Principal Executive Officer of X4 Pharmaceuticals, effective August 12, 2025. He previously served at CTI BioPharma, where he spearheaded a restructuring, oversaw the approval and launch of its initial product, and guided its acquisition by Sobi for $1.7 billion. Dr. Craig brings extensive strategic experience in the life sciences sector and expertise in operational turnarounds.

David Kirske Chief Financial Officer, Secretary

Mr. Kirske assumed the role of Chief Financial Officer and Secretary on August 12, 2025. Prior to joining X4 Pharmaceuticals, he was the Chief Financial Officer of Stratus Therapeutics and also served as Executive Vice President and CFO of CTI BioPharma, where he played a pivotal role in its $1.7 billion acquisition by Sobi. His background includes CFO consulting and senior financial positions at Helix BioMedix, F-5 Networks, Redhook Brewery, and Cray Computer, bringing over two decades of strategic financial and operational experience.

John Volpone President, Chief Operating Officer

Mr. Volpone was appointed President and Chief Operating Officer, effective August 12, 2025. He also previously served at CTI BioPharma, most recently as Executive Vice President and Chief of Staff, overseeing business development, regulatory affairs, and clinical operations. Mr. Volpone has over two decades of cross-functional drug development leadership experience in oncology and rare diseases, including earlier business development roles at Bristol-Myers Squibb and ZymoGenetics.

Art Taveras, Ph.D. Chief Scientific Officer

Dr. Taveras has served as the Chief Scientific Officer of X4 Pharmaceuticals since November 2020. He joined X4 from CoMET Therapeutics, where he held the position of Chief Scientific Officer. Earlier in his career, Dr. Taveras was the Founder and Chief Scientific Officer at Transform Therapeutics and served as President and Chief Scientific Officer at ShangPharma ChemPartner. He also held leadership roles at Biogen Idec and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Dr. Taveras brings over 30 years of experience in leading small molecule research and development programs.

The key risks to X4 Pharmaceuticals (XFOR) are primarily concentrated around the successful development and commercialization of its lead product candidate, mavorixafor (marketed as XOLREMDI for WHIM syndrome).

1. Clinical Trial and Regulatory Risks for Mavorixafor: The company's future success is heavily dependent on the positive outcomes of ongoing and future clinical trials for mavorixafor, particularly for the chronic neutropenia (CN) indication which is currently in Phase 3. There is inherent uncertainty in biopharmaceutical development, and clinical trials may fail to demonstrate the safety and efficacy required for regulatory approval, or they may face delays or rejections. Furthermore, mavorixafor has known safety concerns, including embryo-fetal toxicity and QTc prolongation, which are communicated in its labeling and require careful patient monitoring. The management and perception of these risks could impact the drug's adoption and market potential even after approval.

2. Reliance on a Single Product Candidate: X4 Pharmaceuticals is highly reliant on mavorixafor (XOLREMDI) for its current and projected revenue streams. While XOLREMDI has received FDA approval for WHIM syndrome, the company's broader growth and profitability are tied to expanding mavorixafor's indications, notably into the larger chronic neutropenia market. Should mavorixafor encounter significant setbacks in development or commercialization for these additional indications, the company’s business and financial condition would be materially and adversely affected.

3. Financial Viability and Need for Additional Capital: X4 Pharmaceuticals is currently unprofitable and has experienced shareholder dilution in the past. Although the company has recently secured funding expected to last through key milestones, it faces ongoing financial challenges, including covering operational expenses and funding its extensive clinical development programs. Sustaining operations and executing its long-term strategy will require achieving sufficient revenue from its approved and pipeline products or securing additional capital, which may not always be available on favorable terms or at all.

X4 Pharmaceuticals (symbol: XFOR) develops novel therapeutics for rare diseases. The addressable markets for its main products are as follows:

• Mavorixafor for WHIM Syndrome: The global WHIM syndrome treatment market was valued at USD 0.5 billion in 2024 and is projected to reach USD 1.2 billion by 2034. Within the 7 major markets (U.S., EU4, U.K., and Japan), the market reached USD 9.2 million in 2024 and is expected to grow to USD 16.1 million by 2035. The U.S. market alone for WHIM syndrome was approximately USD 4.8 million in 2023.
• Mavorixafor for Chronic Neutropenia: The addressable market for symptomatic chronic neutropenia patients in the U.S. is estimated at 15,000 patients. The global neutropenia treatment market was valued at USD 14.5 billion in 2023 and is projected to grow to over USD 20.26 billion by 2029. The North America neutropenia treatment market is expected to surpass USD 7.4 billion by 2032.
• Mavorixafor for Waldenström Macroglobulinemia: The global Waldenström macroglobulinemia market is valued at approximately USD 1.2 billion. The global Waldenstrom's macroglobulinemia (WM) treatment market was valued at approximately $800 million in 2023 and is projected to reach $1.3 billion by 2030. The 7 major markets (7MM) for Waldenstrom macroglobulinemia reached a value of USD 158.2 million in 2024 and are expected to reach USD 246.5 million by 2035.
• X4P-002 for Brain Cancers: The global brain cancer market is estimated to be valued at USD 4,761.4 million in 2026 and is expected to reach USD 6,586.6 million by 2033. The global brain tumor treatment market size was valued at USD 3.55 billion in 2025 and is projected to reach USD 7.17 billion by 2035. The U.S. brain tumor treatment market was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.85 billion by 2035.
• X4P-003 for CXCR4 Disorders and Primary Immunodeficiencies: The global primary immunodeficiency disorders market size was valued at USD 7.15 billion in 2023 and is projected to grow. More recently, the global primary immunodeficiency disorders market size was valued at USD 8.85 billion in 2024 and is anticipated to reach around USD 16.93 billion by 2034. North America dominated the global market, accounting for 45.39% of the revenue share in 2023. The U.S. market reached USD 2.9 billion in 2024.

X4 Pharmaceuticals (NASDAQ: XFOR) is positioned for potential revenue growth over the next 2-3 years, primarily driven by its lead product candidate, mavorixafor. Key drivers include the ongoing commercialization of its approved therapy for WHIM syndrome and the progression of mavorixafor in additional indications and new geographies.

The expected drivers of future revenue growth for X4 Pharmaceuticals are:

1. Continued Commercialization of XOLREMDI (mavorixafor) for WHIM Syndrome in the U.S.: X4 Pharmaceuticals received FDA approval for XOLREMDI (mavorixafor) capsules for the treatment of WHIM syndrome in patients 12 years of age and older in April 2024, with the product launched in May 2024. While the company announced a deprioritization of its direct commercialization focus for WHIM syndrome in November 2025 to shift focus to chronic neutropenia, maintaining patient access means any continued uptake and market penetration in the U.S. will contribute to revenue growth.
2. European Union Approval and Commercialization of Mavorixafor for WHIM Syndrome through Norgine Partnership: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for mavorixafor for WHIM syndrome in the EU in February 2026, with a final approval decision anticipated in the second quarter of 2026. X4 has an exclusive licensing and supply agreement with Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals, which is expected to generate revenue through milestones and royalties once approved and launched.
3. Advancement of Mavorixafor in Phase 3 Clinical Trials for Chronic Neutropenia: X4 Pharmaceuticals has strategically shifted its primary focus to the successful completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia. Full enrollment in this trial is expected in the third quarter of 2026, with topline data anticipated in the second half of 2026. Positive clinical trial results and progress toward regulatory submission could trigger development-related milestones or enhance the product's value, paving the way for a potential launch by the end of 2028, which would be a significant revenue driver.

Capital Allocation Decisions for X4 Pharmaceuticals (XFOR) (Last 3-5 Years)

Share Repurchases

Share Issuance

• In October 2025, X4 Pharmaceuticals completed an underwritten public offering, generating approximately $155.3 million in gross proceeds, and also secured an $85 million private placement in Fall 2025.
• In December 2022, the company completed a public offering, raising approximately $65.0 million in gross proceeds.
• On April 28, 2025, X4 Pharmaceuticals enacted a one-for-thirty reverse stock split to meet Nasdaq listing requirements, substantially reducing the number of outstanding shares.

Inbound Investments

• In Fall 2025, X4 Pharmaceuticals raised $85 million through a private placement as part of its financing rounds.
• Through the first three quarters of 2025, the company generated $28.3 million in licensing revenue, largely from an exclusive deal with Norgine for mavorixafor in Europe, Australia, and New Zealand.

Outbound Investments

Capital Expenditures

• In the 12 months leading up to February 2026, X4 Pharmaceuticals reported capital expenditures of approximately $41,000.